Vascular-Endothelial-Growth-Factor-Receptor-2, page 9

Search results for Vascular-Endothelial-Growth-Factor-Receptor-2

Found 3104 articles. Showing from 81 to 90.

Cancer research (2009-02-17)
The plexin-A1 receptor activates vascular endothelial growth factor-receptor 2 and nuclear factor-kappaB to mediate survival and anchorage-independent growth of malignant mesothelioma cells.

Journal of pediatric surgery (2010-02-15)
Vascular endothelial growth factor and bladder from a different perspective: not only an angiogenic factor.

The Journal of trauma (2009-04-10)
Sustained vascular endothelial growth factor blockade by antivascular endothelial growth factor antibodies results in nonunion in the process of fracture healing in rabbits.

Proceedings of the Western Pharmacology Society (2008-07-07)
P2y receptor-mediated angiogenesis via vascular endothelial growth factor receptor 2 signaling.

International journal of radiation oncology, biology, physics (2009-02-13)
The vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor cediranib (Recentin; AZD2171) inhibits endothelial cell function and growth of human renal tumor xenografts.

Clinical cancer research (2008-09-03)
Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase.

American journal of respiratory cell and molecular biology (2004-04-20)
Expression and function of the vascular endothelial growth factor receptor FLT-1 in human eosinophils.

FASEB journal (2011-09-01)
Structural analysis of vascular endothelial growth factor receptor-2/ligand complexes by small-angle X-ray solution scattering.

The Journal of experimental medicine (2002-12-03)
Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis.

Journal of clinical oncology (2009-08-31)
Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.

Filters

Journals

Categories

Subjects

Year of publication

Español | English

© Galenicom 1999-2013